A biomarker of response to earlier alkalyting agents in different types of cancer, i.e., the methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT), is being used today also to predict GBM response to temozolomide and indicate survival.4,5. This evidence concerns the gene MGMT and cancer.